

ADVANCED STRATEGIES IN LONG-TERM MANAGEMENT OF ATRIAL FIBRILLATION

Programme: MSc Public Health and Social Care in Practice

Module name: Community care and Management of longer-term conditions

Module code: LCHS7003

Student name: VAIDEHI JAYMIN PATEL

Student ID: 2534274

Lecturer: MUHAMMED KHAN

INDEX

- SECTION 1: INTRODUCTION, PATHOPHYSIOLOGY, AND EPIDEMIOLOGICAL BURDEN
 - 1.1 Clinical Definition and Pathophysiology of Atrial Fibrillation
 - 1.2 Global and United Kingdom Epidemiological Profiles
 - *Table 1: Quantitative Discrepancies in the UK Atrial Fibrillation Landscape (2025/26 Estimates)*
 - *Figure 1: UK Atrial Fibrillation (AF) Diagnostic & Care Pathway (Infographic)*
 - 1.3 Multifactorial Etiology and Modifiable/Non-Modifiable Risk Factors
 - *Table 2: Mechanistic Classification and Clinical Management of AF Risk Factors*
- SECTION 2: BIOPSYCHOSOCIAL IMPACTS AND NHS TREATMENT PATHWAYS
 - 2.1 Critical Evaluation of Physical, Psychological, and Social Implications
 - *Pie Chart: Etiological Breakdown of Ischemic Strokes*
 - *Table 3: Clinical Breakdown of Ischemic Stroke Categories*
 - 2.2 Impact of Informal Caregiving and Wider Family Dynamics
 - 2.3 Evidence-Based Treatments via the NHS Pathway
- SECTION 3: HEALTHCARE FRAMEWORKS AND POLICY IMPLEMENTATION
 - 3.1 Comparative Analysis of Healthcare Models and Frameworks
 - *Table: Structural Pillars of the House of Care Framework*
 - *Table: Comparative Matrix of Healthcare Frameworks*
 - 3.2 Critical Examination of UK National and Local Political Agendas
- SECTION 4: PERSON-CENTRED APPROACHES AND RECOMMENDATIONS
 - 4.1 Holistic Person-Centred Care and the Social Prescribing Mechanism
 - *Table: Social Prescribing Pathway Milestones*
 - 4.2 Evidence-Based Self-Management Interventions
 - *Figure 2: Strategic AF Pathway: Co-Produced Digital Self-Management (Infographic)*
 - 4.3 End-of-Life Care Considerations in Advanced Frailty
- SECTION 5: STRATEGIC RECOMMENDATIONS FOR PRACTICE
 - 5.1 Strategic Recommendation 1: Community Arrhythmia Clinics
 - 5.2 Strategic Recommendation 2: Co-production of Structured Self-Management Digital Pathways
 - 5.3 Strategic Recommendation 3: Mandated Core Competency Protocols for Anticipatory Care Planning in Advanced Frailty
- SECTION 6: COMPREHENSIVE BIBLIOGRAPHY (HARVARD REFERENCING)

SECTION 1: INTRODUCTION, PATHOPHYSIOLOGY, AND EPIDEMIOLOGICAL BURDEN

1.1 Clinical Definition and Pathophysiology of Atrial Fibrillation

Atrial Fibrillation (AF) is defined as a complex, multi-factorial supraventricular tachyarrhythmia characterized by chaotic, uncoordinated atrial electrical activation with a consequent absolute loss of effective mechanical atrial systole. From an electrophysiological perspective, the homeostatic, uniform depolarization waves initiated by the sinoatrial (SA) node are completely replaced by rapid, high-frequency, disorganized microreentrant electrical circuits or rapidly firing focal triggers. These anomalous impulses predominantly originate within the muscular sleeves of the pulmonary veins situated within the left atrium.

During physiological sinus rhythm, electrical impulses propagate through the atrial syncytium in an orderly manner, generating a distinct P-wave on a surface electrocardiogram (ECG) and promoting a coordinated mechanical contraction that contributes approximately 20% to 30% of total left ventricular end-diastolic volume—a phenomenon known as the "atrial kick". In AF, the electrical firing rate within the atria ranges from 400 to 600 beats per minute (bpm).

The atrioventricular (AV) node, acting as a defensive physiological gatekeeper due to its intrinsic refractory period, cannot conduct this high-volume bombardment. Instead, it conducts these chaotic signals inconsistently, resulting in an irregularly irregular ventricular response, typically oscillating between 110 and 180 bpm in untreated acute states.

The mechanical consequence of this rapid, uncoordinated electrical activity is a complete loss of organized atrial contraction (atrial systole), precipitating structural stasis of blood within the left atrial appendage (LAA). Over time, sustained rapid rates and turbulent flow patterns lead to a profound progressive state known as atrial remodeling. This remodeling operates via three distinct yet interconnected pathways:

- **Electrical Remodeling:** Driven by intracellular calcium (Ca^{2+}) overload due to high firing rates, which downregulates the L-type calcium channels, shortens the atrial effective refractory period (AERP), and further stabilizes the micro-reentrant circuits. This process underpins the classic clinical maxim: "AF begets AF".
- **Structural Remodeling:** Defined by progressive interstitial fibrosis, myofibroblast proliferation, and extracellular matrix deposition within the atrial tissue, heavily mediated by the activation of the renin-angiotensin-aldosterone system (RAAS) and transforming growth factor-beta 1 ($\text{TGF-}\beta_1$) pathways. Fibrosis permanently disrupts electrical continuity, slowing conduction velocity and establishing a fixed anatomical substrate for chronic arrhythmia.
- **Functional Stasis:** Marked by a total loss of mechanical contractility, causing endothelial dysfunction and activating a local prothrombotic state.

Clinically, AF is categorized into four distinct chronological and phenotypic phases, each requiring distinct management approaches:

- **Paroxysmal AF:** Characterized by recurrent episodes that terminate spontaneously or with intervention within 7 days, often within 48 hours.
- **Persistent AF:** Defined by continuous episodes that last longer than 7 days and do not terminate spontaneously, requiring pharmacological or electrical cardioversion to restore normal sinus rhythm.
- **Long-standing Persistent AF:** Continuous, unremitting AF lasting for more than 12 months where a rhythm control strategy is still actively pursued.
- **Permanent AF:** Present when both the patient and the multidisciplinary clinical team accept the presence of the arrhythmia, making rhythm control strategies no longer a realistic or desired objective, and shifting the focus to long-term ventricular rate control.

Recent international consensus guidelines from the European Society of Cardiology (ESC) and the European Heart Rhythm Association (EHRA) have added further detail to these categories by establishing a formalized definition of "AF Burden". Rather than evaluating AF as a static, categorical condition, contemporary clinical models define AF burden as the exact percentage of time an individual experiences the arrhythmia within a continuous monitoring window of at least 28 days. This quantitative measurement is highly relevant because a higher percentage burden correlates directly with accelerated structural remodeling, progressive cognitive decline, and elevated long-term thromboembolic risks.

1.2 Global and United Kingdom Epidemiological Profiles

The contemporary epidemiological data for 2026 confirms that AF has escalated into a major public health epidemic. Globally, the European Society of Cardiology (ESC) and the Global Burden of Disease (GBD) datasets indicate that the absolute number of individuals living with AF stands at approximately 59 million. Projections suggest a steep upward trajectory, with estimates indicating a rise of over 60% by the year 2050, driven heavily by global population aging, increased survival rates from ischemic heart disease, and the rising prevalence of metabolic syndromes. Epidemiologists now emphasize that 1 in 3 individuals worldwide will develop a cardiac rhythm disorder—predominantly AF—during their lifetime.

As documented in clinical registries, public health bodies emphasize that the "true" prevalence of Atrial Fibrillation within the United Kingdom is substantially higher than standard registers suggest—estimated to be between 3.0% and 3.5%. This discrepancy exists because of a massive sub-clinical, hidden burden of "silent" or entirely asymptomatic AF.

As a direct consequence of this diagnostic blind spot, an estimated 300,000 to 500,000 individuals across the UK remain completely undiagnosed and unmedicated, leaving them exposed to a severe risk of preventable cardiovascular events, such as acute ischemic strokes or sudden tachycardiomyopathy.


AF Population Metric (UK)	Data Value (Estimate)	Clinical/Operational Significance	Data Source (Referencing Section 6)
Diagnosed/Registered AF Population	1,427,589 Patients	Represents the clinical cohort actively managed on GP registers and enrolled on QOF performance pathways[cite: 1].	(NHS England, 2025/26)[cite: 1]
Undiagnosed/"Silent" AF Population	~500,000 Citizens	The highest-risk sub-clinical cohort, exposed to unpredictable cardiovascular events without anticoagulation[cite: 1].	(Grand View Research, 2026); (A Alliance, 2026)[cite: 1]
Total Estimated UK Prevalence	~1.9 to 2.0 Million	Combines diagnosed and estimated undiagnosed cohorts; reflects a population prevalence of ~3.0-3.5%[cite: 1].	(Lane et al., 2015); (DHSC, 2025)[cite: 1]
Untreated Heart Rate (Acute State)	110 – 180 bpm	The baseline rapid ventricular response requiring immediate rate control to prevent tachycardiomyopathy[cite: 1].	(Wijffels et al., 1995)[cite: 1]
Annual AF Healthcare Expenditure (UK)	~£2.3 to £3.1 Billion	Includes direct costs of primary care, emergency admissions,	(ResearchGate, 2025)[cite: 1]

		PFA procedures, and post-stroke rehabilitation[cite: 1].	
Proportion of Total NHS Budget	0.9% – 1.6%	Reflects the immense and growing financial strain AF places on the UK healthcare system[cite: 1].	(Open Heart, 2026)[cite: 1]
QOF Anticoagulation Trigger Score	CHA ₂ DS ₂ -VASc ≥ 2	The mandatory threshold for initiating oral anticoagulation to secure QOF AF008 indicator points[cite: 1].	(NICE, 2021); (NHS England, 2025)[cite: 1]

TABLE 1: Quantitative Discrepancies in the UK Atrial Fibrillation Landscape (2025/26 Estimates)

The underlying distribution of AF across the demographic spectrum exhibits a steep, age-dependent gradient, corroborating clinical registry values:

- **Under 50 years:** Highly uncommon (< 1%), typically presenting as "lone AF" secondary to acute hemodynamic triggers, extreme endurance training, or strong genetic predispositions.
- **Ages 65–70:** Rises sharply to approximately 5.0%, where it begins to dominate primary care chronic disease workloads.
- **Over 75–80 years:** Exceeds 10% to 12%, making it an almost ubiquitous comorbidity within the geriatric multi-morbid population profile.
- Gender disparities are also well-documented; the age-adjusted incidence and absolute prevalence are consistently higher in men (approximately 1.1% vs 0.8% in crude population samples). However, because women have a longer average life expectancy, the absolute number of women living with chronic AF in the oldest demographics matches or exceeds that of men. Furthermore, data indicates that women experience higher all-cause mortality, a higher relative risk of stroke, and more severe symptom profiles than men with identical baseline characteristics.



Ethnically, historical epidemiological datasets demonstrate a lower apparent prevalence of AF in Black, Asian, and minority ethnic populations compared to white Caucasian populations, even when adjusting for traditional cardiovascular risk profiles. However, health inequalities research in the UK cautions that this gap may partly reflect variations in healthcare-seeking behaviors, lower rates of opportunistic pulse checking in underserved communities, and systemic diagnostic disparities rather than pure biological variation.

From a health economics perspective, the financial strain that AF places on the UK healthcare system is immense. Recent health economics models show that direct healthcare expenditures dedicated to managing AF and its direct complications consume between 0.9% and 1.6% of the total NHS annual budget. Projections indicate that by 2030, this economic burden will escalate to between £2.3 billion and £3.1 billion annually, driven primarily by long-term emergency hospital admissions, specialized surgical interventions, and post-stroke residential rehabilitation care.

1.3 Multifactorial Etiology and Modifiable/Non-Modifiable Risk Factors

The development of Atrial Fibrillation represents the convergence of irreversible constitutional traits and modifiable hemodynamic, metabolic, and environmental influences.

Risk Factor Classification	Clinical Variable	Pathophysiological Mechanism & Cellular Impact	Targeted Clinical Intervention / Management Strategy
Non-Modifiable	Advanced Age	Triggers cell senescence within the cardiac conduction system, myocyte apoptosis, and progressive replacement interstitial fibrosis.	Proactive, opportunistic pulse checking and digital screening (e.g., in patients over 65) to bypass the sub-clinical diagnostic blind spot.
Non-Modifiable	Male Biological Sex	Correlates with larger baseline left atrial volumes relative to body surface area, offering a wider anatomical footprint for microreentrant circuits.	Heightened clinical vigilance during routine physicals; gender-stratified risk modification within the CHA ₂ DS ₂ -VASc framework.
Non-Modifiable	Genetics	Single-nucleotide polymorphisms (SNPs) near <i>PITX2</i> and <i>ZFHX3</i> alter cardiac ion-channel expression and early chamber development.	Detailed family history mapping to identify candidates for early-onset or "lone AF" screening protocols.
Modifiable	Systemic Hypertension	Increases left ventricular afterload, driving concentric myocyte hypertrophy, elevated backpressure, mechanical stretch, and chamber dilation.	Aggressive blood pressure control using RAAS inhibitors (ACE inhibitors/ARBs) to minimize structural remodeling and secure QOF indicator targets.
Modifiable	Obesity	Drives low-grade systemic inflammation and accumulation of epicardial adipose tissue (EAT) that directly infiltrates the myocardium.	Structured lifestyle and weight management interventions, often facilitated by Primary Care Link Workers via social prescribing pathways.
Modifiable	Alcohol Consumption	Exerts direct toxic effects on atrial cardiomyocytes, altering cell-surface membranes and destabilizing cardiac electrical continuity.	Patient education regarding complete abstinence or strict moderation to reduce the frequency and severity of paroxysmal "Holiday Heart" episodes.

TABLE 2: Mechanistic Classification and Clinical Management of AF Risk Factors

Non-Modifiable Structural and Genetic Drivers

- **Advanced Age:** Aging triggers cell senescence within the cardiac conduction system. It leads to myocyte hypertrophy, apoptosis, and increased replacement interstitial fibrosis, which permanently slows intra-atrial conduction velocity.
- **Male Biological Sex:** Men possess larger baseline left atrial volumes relative to total body surface area, which provides a larger anatomical footprint that can accommodate multiple concurrent electrical microreentrant circuits.
- **Genetic Predispositions:** Genome-wide association studies (GWAS) have isolated over 100 distinct single-nucleotide polymorphisms (SNPs) associated with early-onset or "lone" AF. Notable examples include mutations localized around the *PITX2* (paired-like homeodomain transcription factor 2) and *ZFHX3* (zinc finger homeobox 3) genes, which regulate cardiac ion-channel expression and early chamber development.

Modifiable Hemodynamic and Metabolic Stressors

- **Systemic Hypertension:** This remains the single most common modifiable contributor, present in nearly 80% of individuals diagnosed with AF. Chronic, uncontrolled arterial hypertension escalates left ventricular afterload, promoting concentric left ventricular hypertrophy. This reduces myocardial compliance, raising left ventricular end-diastolic pressure. The resulting backpressure causes mechanical stretch, dilatation, and localized ischemia within the left atrium, triggering structural remodeling.
- **Obesity and Adipose Tissue Deposition:** An elevated Body Mass Index (BMI) directly correlates with a linear increase in AF risk. For every 5-unit increase in BMI, the relative risk of developing AF escalates by 4% to 5%. Obesity drives AF via systemic low-grade inflammation, increased total blood volume, and the accumulation of epicardial adipose tissue (EAT). This local fat tissue directly infiltrates the atrial myocardium, releasing proinflammatory adipokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α), which disrupt local electrical signaling.
- **Obstructive Sleep Apnea (OSA):** Present in up to 50% of patients referred for rhythm management, OSA exposes the atria to severe nocturnal hypoxia, systemic hypercapnia, and sharp surges in negative intrathoracic pressure. This combination results in acute atrial stretching, vagal-sympathetic imbalance, and paroxysmal arrhythmia triggers.
- **Chronic Alcohol Consumption:** Long-term excessive alcohol intake exerts direct toxic effects on atrial cardiomyocytes, altering cell-surface myocyte membranes. Even moderate, consistent consumption (e.g., 1–2 units daily) can lead to progressive atrial remodeling, while acute binge drinking can precipitate atrial arrhythmias, a phenomenon clinically termed "Holiday Heart Syndrome".
- **Endocrine Dysfunctions (Hyperthyroidism):** Elevated circulating thyroxine (T_4) and triiodothyronine (T_3) sensitize myocardial β -adrenergic receptors, increasing resting heart rates and atrial excitability.


SECTION 2: BIOPSYCHOSOCIAL IMPACTS AND NHS TREATMENT PATHWAYS

2.1 Critical Evaluation of Physical, Psychological, and Social Implications

Physical Implications and the Thromboembolic Cascade

The physical consequences of Atrial Fibrillation are led by a highly elevated risk of thromboembolic events, specifically ischemic cerebrovascular accidents (strokes). Because the left atrial appendage loses mechanical contractility during AF, blood pools and stasis occurs. This environment promotes thrombus formation. This pathology aligns directly with Virchow's Triad: endothelial dysfunction, circulatory stasis, and systemic hypercoagulability.

Etiological Breakdown of Ischemic Strokes Highlighting the Dominance of AF-Induced Thromboembolism



Ischemic Stroke Etiology	Population Share (%)	Pathophysiological Mechanism Related to Pathway	Clinical Modifier	Outcome
Atrial Fibrillation / Cardioembolic	30.0%	Atrial stasis within the LAA leads to a rapid thrombus formation that breaks loose, causing direct occlusion of the Middle Cerebral Artery (MCA).	Highest	severity: Doubles 30-day mortality and increases permanent disability risks by 50%.
Small Vessel Occlusion (Lacunar)	25.0%	Chronic hypertension causes lipohyalinosis of deep penetrating arteries within the brain.	Typically lower initial mortality but high cumulative cognitive impact.	
Large Artery Atherosclerosis	20.0%	Extracranial (carotid) or intracranial plaque rupture triggers localized thrombotic occlusion.	High risk of recurrent transient ischemic attacks (TIAs) if unmanaged.	
Cryptogenic / Undetermined	20.0%	Stroke of unknown origin, often suspected to be hidden or "silent" paroxysmal AF that went undetected.	Requires prolonged continuous ECG or smartwatch monitoring to rule out silent AF.	
Other Determined Etiologies	5.0%	Non-atherosclerotic conditions such as vascular dissection, hypercoagulable states, or vasculitis.	Treatment depends entirely on the specific	

			underlying systemic pathology.
--	--	--	--------------------------------

TABLE 3: Clinical Breakdown of Ischemic Stroke Categories

When a fragment of an intra-atrial thrombus breaks loose, it enters the systemic arterial circulation and frequently occludes the middle cerebral artery (MCA). This mechanism accounts for approximately 20% to 30% of all ischemic strokes. Furthermore, AF-related strokes are associated with poorer clinical outcomes than non-AF strokes: they carry a 50% higher risk of permanent disability, a twofold increase in 30-day mortality, and a substantially higher rate of recurrence.

Beyond thromboembolism, sustained rapid ventricular rates reduce diastolic filling time, impairing coronary perfusion and dropping cardiac output by 20% to 25% due to the loss of the "atrial kick". This frequently precipitates or worsens tachycardiomyopathy and chronic heart failure. On an individual level, patients suffer from chronic physical fatigue, exertional dyspnea, dizzy spells, and chest palpitations, which limit mobility and reduce independence in activities of daily living (ADLs).

Psychological Manifestations and the Anxiety-Arrhythmia Loop

The psychological impact of AF is significant but often underrecognized in routine clinical consultations. Longitudinal studies show that between 30% and 40% of diagnosed AF patients experience high levels of anxiety, and up to 25% meet clinical criteria for major depressive disorder. The unpredictable, episodic nature of paroxysmal AF creates a state of continuous hyper-vigilance. Patients often describe living in fear of the next episode, misinterpreting normal sinus fluctuations as a sign of an impending cardiac emergency. This cycle can lead to panic disorders and avoidance behaviors.

Paroxysmal AF Episode —► Hypervigilance & Fear —► Sympathetic Nervous Overdrive —► Trigger for Recurrent AF

This psychological distress sets up a dangerous feedback loop: the emotional panic triggers a surge in endogenous catecholamines, increasing sympathetic nervous system activity, which can then precipitate a recurrent episode of AF.

Furthermore, introducing long-term oral anticoagulation therapy adds psychological stress related to bleeding risks. Patients often worry about hemorrhagic stroke, internal bleeding from minor falls, or standard drug-nutrient interactions. This fear can negatively affect treatment adherence and reduce overall quality of life. Recent studies have highlighted that up to 20% of symptomatic AF patients experiencing severe psychological distress report passive suicidal ideation, underlining the need for integrated psycho-cardiac support.

Social Repercussions and Quality of Life Impairment

Socially, AF can lead to social isolation and reduced community engagement. Exertional breathlessness and fatigue often force individuals to withdraw from recreational activities, social clubs, and volunteer roles, shrinking their supportive social networks. For younger, working-age patients, frequent symptomatic episodes can result in high rates of absenteeism, decreased productivity, and early retirement, causing financial strain.

Sexual dysfunction is another common but underreported issue, driven by a combination of performance-related anxiety, physical exhaustion, and the side effects of rate-controlling medications such as β -blockers. This can place extra strain on intimate relationships and marital stability.

2.2 Impact of Informal Caregiving and Wider Family Dynamics

The burden of managing chronic AF extends beyond the individual patient, often reshaping the entire family structure. In the UK, informal caregivers—typically spouses, adult children, or close cohabitants—provide vital daily support, but often at a high personal cost.

Family caregivers routinely take on a wide range of tasks, including managing complex medication schedules, coordinating medical appointments, monitoring for signs of stroke or bleeding, and assisting

with basic physical mobility. This continuous responsibility can lead to informal caregiver burnout, a multi-dimensional state of physical, emotional, and mental exhaustion. Caregivers frequently report chronic sleep deprivation, especially if the patient experiences nocturnal paroxysms or sleep apnea. They also face a higher risk of developing anxiety and stress-related physical health conditions themselves.

Complex AF Regimen —► Caregiver Hyper-vigilance —► Chronic Stress & Sleep Loss —► Caregiver Burnout

Family dynamics often shift significantly. Spouses may transition from equal partners to full-time care providers, disrupting long-standing marital roles and creating unspoken feelings of dependency and resentment. The continuous anxiety surrounding stroke risk can create a tense home environment, where family members become overly protective, restricting the patient's remaining independence out of fear.

Additionally, the financial impact on families can be substantial, particularly if a working-age caregiver must reduce their working hours or leave employment entirely to balance caregiving duties. This reduction in household income occurs alongside rising care-related costs, such as transport to specialist clinics.

2.3 Evidence-Based Treatments via the NHS Pathway

The clinical management of AF within the UK healthcare system is standardized by the National Institute for Health and Care Excellence (NICE) NG196 guidelines. Treatment plans are structured around three core pillars: stroke prevention through anticoagulation, ventricular rate control, and atrial rhythm restoration.

Stroke Prevention and Anticoagulation

NICE guidelines require that stroke risk be formally assessed for every patient using the electronic clinical prediction tool, the CHA₂DS₂-VASc score, which assigns points based on clinical risk factors:

- Congestive heart failure (1 point)
- Hypertension (1 point)
- Age ≥ 75 years (2 points)
- Diabetes mellitus (1 point)
- Stroke/TIA/Thromboembolism history (2 points)
- Vascular disease (1 point)
- Age 65–74 years (1 point)
- Sex category [Female] (1 point)

Anticoagulation is strongly recommended for men with a CHA₂DS₂-VASc score of 1 and mandated for all patients with a score of ≥ 2 . Crucially, female sex alone is treated as a risk modifier rather than an independent trigger for therapy. Concurrently, a patient's baseline bleeding risk must be quantified using the ORBIT bleeding score or the HAS-BLED calculator. This allows clinicians to identify and address modifiable bleeding risks—such as uncontrolled hypertension, concurrent NSAID usage, or excessive alcohol intake—rather than using an elevated score as a reason to withhold necessary anticoagulation.

Direct Oral Anticoagulants (DOACs)—including Apixaban, Rivaroxaban, Edoxaban, and Dabigatran—are recommended by NICE as first-line therapies, completely superseding traditional Vitamin K Antagonists like Warfarin, except in cases of mechanical heart valves or moderate-to-severe mitral stenosis. DOACs offer a superior safety profile, lower rates of intracranial hemorrhage, predictable pharmacokinetics, and eliminate the need for regular International Normalized Ratio (INR) blood testing.

Ventricular Rate Control

For the majority of elderly or minimally symptomatic patients, a rate-control strategy is deployed as the standard first-line long-term approach. The primary therapeutic goal is to achieve a resting heart rate of < 110 bpm in asymptomatic individuals, or a stricter target of < 80 bpm if symptoms persist or features of heart failure are present.

- **First-Line Monotherapy:** Cardioselective β -blockers, such as Bisoprolol or Metoprolol, are the preferred choice. They slow AV node conduction by blocking sympathetic inputs. Alternatively, rate-limiting (non-dihydropyridine) calcium channel blockers, such as Diltiazem or Verapamil, are used in patients without structural heart disease or reduced ejection fraction.
- **Adjunctive Therapy:** Digoxin can be added when monotherapy fails to control the ventricular rate. Digoxin works by increasing vagal tone to slow the AV node. It is particularly useful for sedentary patients with concurrent heart failure, though regular serum monitoring is required to prevent digitalis toxicity.

Atrial Rhythm Control

A rhythm-control strategy aims to actively restore and maintain normal sinus rhythm. This approach is typically reserved for younger individuals, highly symptomatic patients, those presenting with new-onset AF, or cases where tachycardiomyopathy has caused secondary heart failure.

- **Pharmacological Cardioversion / Antiarrhythmic Drugs (AADs):** Flecainide (a Class 1C fast sodium-channel blocker) is frequently used, but it is strictly contraindicated in patients with pre-existing structural or ischemic heart disease due to pro-arrhythmic risks. For patients with structural heart disease, Amiodarone (a Class III potassium-channel blocker) is the primary option, though its long-term use is limited by potential toxicities affecting the thyroid, lungs, liver, and skin.
- **Electrical Cardioversion (DCCV):** Direct Current Cardioversion involves delivering a synchronized electrical shock across the chest wall under conscious sedation to reset the cardiac conduction system. To minimize thromboembolic risk, patients must be therapeutic on anticoagulation for at least three consecutive weeks prior to the procedure.
- **Catheter Ablation:** For patients who remain highly symptomatic despite drug therapy, or as a first-line option in selected cases of paroxysmal AF, percutaneous catheter ablation is increasingly utilized within the NHS. This procedure involves passing an ablation catheter via the femoral vein into the left atrium. Using radiofrequency energy (heat) or cryoablation (extreme cold), the operator isolates the pulmonary veins, creating circumferential lines of scar tissue that block abnormal electrical triggers from entering the atrial myocardium.

Recently, NICE has updated its procedural guidance to support Pulsed Field Ablation (PFA) as an alternative to thermal ablation within the NHS. Unlike traditional radiofrequency or cryo-energy, PFA uses ultra-rapid, tissue-selective electrical fields to punch microscopic holes in cell membranes (electroporation). Because cardiac muscle cells are highly sensitive to this energy compared to nearby structures, PFA isolates the pulmonary veins quickly while minimizing the risk of serious complications like esophageal perforation or phrenic nerve injury. This technology helps shorten waiting lists and reduce overall hospital costs.

SECTION 3: HEALTHCARE FRAMEWORKS AND POLICY IMPLEMENTATION

3.1 Comparative Analysis of Healthcare Models and Frameworks

Improving outcomes for individuals living with chronic, multi-morbid conditions like AF requires moving away from reactive, episodic acute care toward proactive, integrated healthcare models. Two major frameworks help guide this transformation: the House of Care Model within the UK and the international Chronic Care Model (CCM).

The UK House of Care Framework

The House of Care framework was developed by the King's Fund and adopted widely across NHS England. It uses the metaphor of a house to represent the interconnected components needed to deliver effective, person-centered care for long-term conditions.

- **The Roof:** Represents the commissioning framework, ensuring that financial and structural incentives are aligned to support integrated care.

Component / Pillar	Clinical & Operational Role in AF Care
Roof: Commissioning	Aligns local funding, ICB resources, and clinical incentives to support integrated, long-term cardiovascular care pathways rather than isolated acute treatments.
Wall 1: Health Professionals	Empowers multidisciplinary teams (ANPs, GPs, pharmacists) to act as collaborative clinical partners rather than top-down instructors.
Wall 2: Engaged Patient	Builds the patient's health literacy, confidence, and self-efficacy to actively manage lifestyle changes, track symptoms, and adhere to DOAC regimens.
Foundation: System Info	Utilizes shared electronic health records, risk analytics, and clinical disease registries (like QOF) to track progress and prevent patients from falling out of care.
The Core: Collaborative Plan	Forms the heart of the model—a personalized, shared decision-making conversation to set realistic, patient-centered goals.

- **The Left Wall:** Represents the health and social care professionals, who must possess the clinical competencies, communication skills, and collaborative mindset to act as partners rather than instructors.
- **The Right Wall:** Represents the engaged, informed patient, equipped with the knowledge, confidence, and self-efficacy to actively manage their health.
- **The Floor/Foundation:** Represents the essential data infrastructure, including shared electronic health records, predictive risk analytics, and clinical registries that track population outcomes.
- **The Core:** At the center of the house is the collaborative care planning conversation, where clinicians and patients work together to set personalized, realistic goals.

When applied to AF, this model ensures that an annual review is not just a checklist of clinical markers. Instead, it becomes a meaningful dialogue about lifestyle modification, medication adherence, and early symptom recognition, fully aligning with the NHS personalization agenda.

The International Chronic Care Model (CCM)

Developed by Edward Wagner in the United States, the Chronic Care Model (CCM) is an internationally recognized framework designed to guide systemic healthcare restructuring. The model emphasizes that high-quality care requires productive interactions between an informed, activated patient and a prepared, proactive team of health professionals. It is built upon six core components:

- **Health System Organization:** Creating a corporate culture that prioritizes patient safety and rewards chronic disease management rather than just acute throughput.

- **Clinical Information Systems:** Utilizing disease registries to track performance, schedule preventive services, and identify patients who have fallen out of regular follow-up.
- **Delivery System Design:** Restructuring clinical encounters to clearly separate acute care from planned chronic disease management, often by expanding the roles of specialist nurses and clinical pharmacists.
- **Decision Support:** Embedding evidence-based clinical guidelines directly into electronic medical records to reduce unwarranted clinical variation.
- **Self-Management Support:** Emphasizing the patient's central role in managing their condition through goal-setting, action planning, and problem-solving.
- **Community Resources and Policies:** Linking healthcare organizations with community-based assets, such as exercise programs, smoking cessation groups, and peer support networks.

Attribute Focus /	The UK House of Care Model DOCX	The International Chronic Care Model (CCM) DOCX
Primary Origin	Built specifically for the NHS context (The King's Fund, 2013).	Developed in the US, widely adopted globally (Wagner et al., 2001).
Structural Metaphor	Uses an integrated house structure to stress that if one component fails, the entire system collapses.	Consists of six distinct, overlapping components influencing a central productive interaction.
Operational Focus	Focuses heavily on the collaborative care planning encounter at the center.	Places strong emphasis on system-level reorganization and electronic registries.
Community Linkage	Integrates social prescribing directly into the clinical care planning process.	Emphasizes external community resources as an independent structural pillar.

Table : Comparative Matrix of Healthcare Frameworks

3.2 Critical Examination of UK National and Local Political Agendas

The management of AF is directly influenced by national healthcare policies and local operational agendas across the UK.

The NHS Long Term Plan (LTP)

The NHS Long Term Plan places a major focus on preventing cardiovascular disease (CVD), identifying it as the single largest area where the NHS can save lives over a ten-year period. A core objective of the plan is to prevent up to 150,000 heart attacks, strokes, and dementia cases.

To achieve this, the plan mandates a major expansion of opportunistic and targeted screening for the "ABC" conditions: Atrial Fibrillation, Blood Pressure, and Cholesterol. In practice, this policy has shifted funding toward deploying digital health tools in primary care, such as mobile ECG devices (e.g., AliveCor KardiaMobile) and wearable pulse monitors, allowing for rapid detection of undiagnosed AF during routine appointments.

Integrated Care Systems (ICS) and Local ICBs

Under the Health and Care Act 2022, the establishment of Integrated Care Systems (ICSs) and Integrated Care Boards (ICBs) replaced old Clinical Commissioning Groups (CCGs). This structural reform aims to break down traditional institutional barriers between primary care, secondary hospital trusts, and social care services.

For AF management, this model allows ICBs to commission integrated, area-wide clinical pathways. Rather than managing a patient through disconnected visits to a GP, a hospital cardiologist, and a social worker, local pathways now utilize cross-functional community networks. These networks include community pharmacists who screen for AF during medication reviews, rapid-access arrhythmia clinics, and integrated stroke prevention teams, ensuring smoother care transitions.

The Quality and Outcomes Framework (QOF)

The Quality and Outcomes Framework (QOF) serves as a key financial incentive mechanism within UK general practice, directly shaping how primary care teams prioritize long-term conditions. For the current financial year, the AF domain contains specific, high-value indicators that drive clinical behavior:

- **Indicator AF007:** Requires primary care practices to maintain an accurate, up-to-date register of all patients with a documented diagnosis of AF.
- **Indicator AF008:** Incentivizes practices to ensure that all patients with an AF diagnosis and a CHA₂DS₂-VASc score of ≥ 2 (or 1 in men) are actively prescribed an appropriate oral anticoagulant (DOAC or Warfarin), unless a clear, documented medical contraindication exists.

While QOF has successfully driven up national anticoagulation rates and significantly reduced the number of preventable, AF-related strokes across the country, it faces criticism from public health researchers. Critics argue that QOF can encourage a "tick-box" approach to medicine, prioritizing numerical targets over deep, personalized care. It can also lead to a hyper-focus on single conditions, which may not align with the complex needs of older patients living with multiple, interacting long-term illnesses.

SECTION 4: PERSON-CENTRED APPROACHES AND RECOMMENDATIONS

4.1 Holistic Person-Centred Care and the Social Prescribing Mechanism

Moving from a purely medical model to a holistic, person-centered approach is essential for effective AF management. This shift requires clinicians to move away from asking "What is the matter with this patient?" and instead focus on "What matters to this patient?" Holistic care treats the individual as an active partner in their health journey, fully acknowledging that their physical symptoms are deeply intertwined with their psychological state, social environment, and financial stability.

A key mechanism within the NHS to support this approach is Social Prescribing, coordinated by primary care Link Workers. Social prescribing recognizes that health is heavily influenced by wider social determinants that cannot be addressed by medication alone.

Stage	Pathway Milestone	Core Operational Objective
1	Primary Care Consultation	GP or nurse identifies non-clinical, social determinants affecting the patient's AF control (e.g., isolation, stress).
2	Link Worker Referral	Patient is connected with a dedicated Social Prescribing Link Worker for a holistic, "what matters to you" assessment.
3	Community Asset Mapping	Link Worker cross-references local community resources to locate safe, tailored options like low-impact cardiac exercise groups.
4	Peer Group Enrolment	Patient actively joins local support networks, reducing anxiety around exertion while strengthening social connection.

TABLE : Social Prescribing Pathway Milestones

For an individual living with AF, a social prescribing pathway might connect them to:

- Local, low-impact exercise classes tailored for cardiac rehabilitation, helping to safely rebuild physical stamina and reduce anxiety around exertion.

- Volunteer networks and peer support groups, reducing the social isolation caused by the unpredictability of their condition.
- Local welfare and debt counseling services, helping to alleviate the financial stress that can worsen hypertension and trigger arrhythmic episodes.


4.2 Evidence-Based Self-Management Interventions

Empowering patients to actively self-manage is crucial for reducing the long-term burden of AF on healthcare systems. Successful self-management relies on providing structured, evidence-based education that builds confidence and health literacy.

Digital Health Tools and Self-Monitoring

The use of consumer technology has transformed AF self-management. Clinically validated smartphone applications and smartwatches equipped with photoplethysmography (PPG) or single-lead ECG monitors allow patients to track their heart rhythm in real-time.

When integrated into a structured care plan, these tools help patients differentiate between benign sinus tachycardia and genuine AF paroxysms, reducing unnecessary Emergency Department attendances. Crucially, digital self-monitoring must be accompanied by a clear "safety-netting" framework, ensuring patients know exactly when a reading warrants routine review versus urgent medical attention.



Structured Educational Programs

Patients require targeted education on a range of essential self-management behaviors:

- **Medication Adherence:** Understanding the short half-life of DOACs is vital; missing even a single dose can rapidly eliminate thromboembolic protection, unlike older medications like Warfarin.
- **Symptom Recognition:** Learning to identify warning signs of major complications, such as an irregular pulse paired with sudden slurred speech or unilateral weakness (indicative of a stroke), alongside recognizing signs of internal bleeding like unexplained bruising or dark, tarry stools.
- **Lifestyle Modification:** Adopting practical strategies for sustainable weight loss, incorporating moderate physical activity, and strictly limiting alcohol and caffeine intake to reduce the frequency and severity of arrhythmic episodes.

4.3 End-of-Life Care Considerations in Advanced Frailty

In the advanced stages of long-term conditions, especially when AF coexists with severe heart failure, multi-infarct dementia, or advanced multi-organ frailty, the clinical focus must shift from prolongation of life to optimization of comfort and quality of life.

Deciding to De-escalate and Deprescribe

As a patient approaches the end of life, the continuing benefit of routine therapies must be carefully reevaluated. Anticoagulation with DOACs or Warfarin, which is maintained for years to prevent stroke, can become a significant hazard in the presence of advanced frailty, frequent falls, or spontaneous bleeding.

In the final weeks or days of life, clinicians, in close consultation with the patient and their family, should actively consider discontinuing oral anticoagulation to minimize the risk of distressing hemorrhagic complications, shifting the therapeutic priority entirely to comfort.

Managing Symptoms in Palliative Care

When rhythm control is no longer appropriate, terminal symptom management focuses on maintaining comfort and reducing distress:

- **Rate Control for Comfort:** Low-dose β -blockers or digoxin may be maintained to prevent rapid, distressing palpitations or acute pulmonary edema, provided the patient can still swallow or medication can be delivered via alternative routes.
- **Alleviating Dyspnea and Anxiety:** Subcutaneous infusions of low-dose opioids (e.g., Morphine) via a syringe driver are highly effective at easing terminal breathlessness, while low-dose benzodiazepines (e.g., Midazolam) can help manage associated anxiety and agitation.

Anticipatory Care Planning (ACP)

Anticipatory Care Planning should be initiated well before a patient reaches the terminal phase, while they still retain full decision-making capacity. Key components of a comprehensive ACP for a patient with advanced cardiovascular disease include:

- **Documenting Care Preferences:** Formally recording the patient's choices regarding preferred place of care and preferred place of death (e.g., home, hospice, or care facility).
- **Treatment Limitations:** Documenting clear decisions regarding hospital readmissions, intravenous antibiotic therapy for recurring infections, and defining a clear Do Not Attempt Cardiopulmonary Resuscitation (DNACPR) status.
- **Legal Protections:** Encouraging the formal appointment of a Lasting Power of Attorney (LPA) for Health and Welfare, ensuring that a trusted family member can advocate for the patient's documented wishes if they lose capacity.

SECTION 5: STRATEGIC RECOMMENDATIONS FOR PRACTICE

5.1 Strategic Recommendation 1: Community Arrhythmia Clinics

- **Rationale:** To operationalize the integrated care goals of the Health and Care Act 2022 and the NHS Long Term Plan, reducing the fragmentation of care across primary and secondary sectors.
- **Action:** Integrated Care Boards (ICBs) should commission community-based clinics where patients can access diagnostic 12-lead ECGs, echocardiography, ORBIT bleeding risk evaluations, and DOAC initiation during a single appointment. This service should be led by Advanced Nurse Practitioners (ANPs) and Specialist Clinical Pharmacists, with a direct communication link to regional cardiology centers.

5.2 Strategic Recommendation 2: Co-production of Structured Self-Management Digital Pathways

- **Rationale:** To strengthen self-management support, fully aligning with the UK House of Care framework by actively engaging and informing patients.
- **Action:** Primary care networks (PCNs) should implement a co-produced digital platform that connects validated wearable devices directly with primary care health records. This platform should feature interactive modules focused on DOAC medication adherence, the dangers of alcohol-induced remodeling, and structured lifestyle goals, supported by asynchronous messaging with a designated care coordinator.

5.3 Strategic Recommendation 3: Mandated Core Competency Protocols for Anticipatory Care Planning in Advanced Frailty

- **Rationale:** To address existing variations in end-of-life care quality, ensuring that person-centered care remains a priority through the final stages of advanced frailty.
- **Action:** General practices should introduce an electronic clinical trigger within their systems. This trigger would mandate an Anticipatory Care Plan review whenever an AF patient aged over 80 experiences two or more unplanned hospital admissions within a six-month period, or displays an ORBIT score indicating high bleeding risk alongside advanced frailty. This review will guide timely decisions on medication optimization, DNACPR status, and local palliative care coordination.

SECTION 6: COMPREHENSIVE BIBLIOGRAPHY (HARVARD REFERENCING)

- Abed, H.S., Wittert, G.A., Leong, D.P., Shirazi, M.G., Bahrami, B., Middeldorp, M.E., Lorimer, M., Lau, D.H., Sanders, P. and Abhayaratna, W.P. (2013) 'Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized controlled trial', *JAMA*, 310(19), pp. 2050-2060.
- Arrhythmia Alliance (2026) *Transforming atrial fibrillation management by targeting comorbidities and reducing atrial fibrillation burden: the 10th AFNET/EHRA consensus conference*. Available at: <https://heartrhythmalliance.org/aa/uk/new-guidelines-issued-for-care-of-atrial-fibrillation-patients> (Accessed: 25 June 2026).
- Barlow, J., Wright, C., Sheasby, J., Turner, A. and Hainsworth, J. (2002) 'Self-management approaches for people with chronic conditions: a review', *Patient Education and Counseling*, 48(2), pp. 177-187.
- Beacon Health System (2025) *Caregiving for someone with atrial fibrillation*. Available at: https://www.beaconhealthsystem.org/library/articles/caregiving-for-someone-with-atrial-fibrillation?content_id=ART20118648 (Accessed: 25 June 2026).
- Boyd, C.M., Darer, J., Boulton, C., Fried, L.P., Boulton, L. and Wu, A.W. (2005) 'Clinical practice guidelines for older adults with multiple chronic diseases: implications for pay for performance', *JAMA*, 294(6), pp. 716-724.
- British Heart Foundation (2026) *Global Cardiovascular Disease Factsheet*. London: BHF. Available at: <https://www.bhf.org.uk/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet-jan26.pdf> (Accessed: 25 June 2026).
- Burstein, B. and Nattel, S. (2008) 'Atrial structural remodeling as an arrhythmogenic substrate for atrial fibrillation', *Journal of the American College of Cardiology*, 51(13), pp. 1225-1236.
- Calkins, H., Hindricks, G., Cappato, R., Kim, Y.H., Saad, E.B., Aguinaga, L., Akar, J.G., Badhwar, V., Brugada, J., Camm, J. and Chen, P.S. (2017) '2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation', *Heart Rhythm*, 14(10), pp. e275-e444.

- Chourdakis, E., Koniari, I., Velissaris, D. and Kounis, N.G. (2024) 'Sex disparities in atrial fibrillation: epidemiology, mechanisms, and clinical outcomes', *Journal of Clinical Medicine*, 13(4), p. 1102.
- Clark, A.M., King-Shier, K.M., Thompson, D.R., Spaling, M.A., Duncan, A.S., Stone, J.A., Jaglal, S.B. and Strain, F.A. (2014) 'A qualitative systematic review of influences on self-care in adults with atrial fibrillation', *European Journal of Cardiovascular Nursing*, 13(5), pp. 412-421.
- Dayson, C. and Bashir, N. (2014) *The social and economic impact of the Rotherham Social Prescribing Pilot*. Sheffield: Sheffield Hallam University.
- Department of Health and Social Care (2025) *Atrial fibrillation: QOF prevalence (All ages) 2024/25*. London: Fingertips Public Health Profiles. Available at: <https://fingertips.phe.org.uk/search/fibrillation> (Accessed: 25 June 2026).
- Ellinor, P.T., Lunetta, K.L., Albert, C.M., Glazer, N.L., Ritchie, M.D., Smith, A.V., Arking, D.E., Müller-Nurasyid, M., Krijthe, B.P., Lubitz, S.A. and Sullivan, L.M. (2012) 'Meta-analysis of genome-wide association studies identifies 10 loci associated with atrial fibrillation', *Nature Genetics*, 44(6), pp. 670-675.
- Epping-Jordan, J.A., Pruitt, S.D., Bengoa, R. and Wagner, E.H. (2004) 'Improving the quality of health care for chronic conditions', *Quality and Safety in Health Care*, 13(4), pp. 299-305.
- European Society of Cardiology (2025) *Global surge in serious heart rhythm disorders sparks urgent call to action from experts: 1 in 3 people at risk*. Sophia Antipolis: ESC Press Office. Available at: <https://www.escardio.org/news/press/press-releases/global-surge-in-serious-heart-rhythm-disorders-sparks-urgent-call-to-action-from/> (Accessed: 25 June 2026).
- GPnotebook (2025) *Paroxysmal atrial fibrillation (AF): Prevalence*. Available at: <https://gpnotebook.com/en-GB/pages/cardiovascular-medicine/paroxysmal-atrial-fibrillation-af/prevalence> (Accessed: 25 June 2026).
- Grand View Research (2026) *UK Atrial Fibrillation Market Size & Outlook, 2026-2033*. London: Grand View Research. Available at: <https://www.grandviewresearch.com/horizon/outlook/atrial-fibrillation-market/uk> (Accessed: 25 June 2026).
- Guo, Y., Wang, H., Zhang, H., Liu, T., Liang, Z., Xing, Y. and Lip, G.Y. (2019) 'Mobile health technology for atrial fibrillation screening Opportunities and challenges', *International Journal of Cardiology*, 282, pp. 47-51.
- Haïssaguerre, M., Jaïs, P., Shah, D.C., Takahashi, A., Hocini, M., Quiniou, G., Garrigue, S., Le Mouroux, A., Le Métayer, P. and Clémenty, J. (1998) 'Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins', *New England Journal of Medicine*, 339(10), pp. 659-666.
- Hindricks, G., Potpara, T., Dagres, N., Arbelo, E., Bax, J.J., Blomström-Lundqvist, C., Boriani, G., Castella, M., Dan, G.A., Dossart, I. and Folliguet, T. (2021) '2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)', *European Heart Journal*, 42(5), pp. 373-498.
- Jaarsma, T., Beattie, J.M., Ryder, M., Hughes, C.M., McDonagh, T., Hamilton, G., Lomas, O., de Walden-Rothenny, S. and Strömberg, A. (2009) 'Palliative care in patients with advanced heart failure', *European Journal of Heart Failure*, 11(5), pp. 433-443.
- Lane, D.A., Skjøth, F., Lip, G.Y., Larsen, T.B. and Kotecha, D. (2015) 'Temporal trends in incidence, prevalence, and mortality of atrial fibrillation in the UK from 2000 to 2012', *The American Journal of Medicine*, 128(12), pp. 1319-1326.

- Lau, D.H., Schotten, U., Mahajan, R., Antic, N.A., McEvoy, R.D., Sanders, P. and Kalman, J.M. (2017) 'Atrial fibrillation in obstructive sleep apnea: mechanisms, clinical significance, and therapeutic implications', *Journal of the American College of Cardiology*, 69(7), pp. 844-856.
- Lip, G.Y. (2014) 'Atrial fibrillation and Virchow's triad revisited: an essential review of thrombogenesis in atrial fibrillation', *Journal of the American College of Cardiology*, 63(23), pp. 2489-2491.
- Lip, G.Y., Brechin, C.M. and Lane, D.A. (2016) 'The global burden of atrial fibrillation', *International Journal of Clinical Practice*, 70(4), pp. 263-267.
- Mayo Clinic (2024) *Atrial fibrillation and managing stress*. Available at: <https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/in-depth/atrial-fibrillation-managing-stress/art-20118647> (Accessed: 25 June 2026).
- Mayo Clinic (2025) *Caregiving for someone with atrial fibrillation*. Available at: <https://www.mayoclinic.org/diseases-conditions/atrial-fibrillation/in-depth/caregiver-atrial-fibrillation/art-20118648> (Accessed: 25 June 2026).
- National Institute for Health and Care Excellence (NICE) (2021) *Atrial fibrillation: diagnosis and management (NICE Guideline NG196)*. London: NICE. Available at: <https://www.nice.org.uk/guidance/ng196> (Accessed: 25 June 2026).
- National Institute for Health and Care Excellence (NICE) (2025) *Pulsed field ablation for atrial fibrillation: Interventional procedures guidance*. London: NICE.
- NHS England (2019) *The NHS Long Term Plan*. London: NHS England.
- NHS England (2025) *Quality and Outcomes Framework guidance for 2025/26*. London: NHS England. Available at: <https://www.england.nhs.uk/wp-content/uploads/2025/03/quality-outcomes-framework-guidance-for-2025-26.pdf> (Accessed: 25 June 2026).
- Open Heart (2026) 'Epidemiology, economic burden and mortality of atrial fibrillation in a region with very high life expectancy: a contemporary, population-based analysis', *Open Heart*, 13(1), pp. e004007[cite: 1].
- ResearchGate (2025) *Atrial Fibrillation in the United Kingdom: Predicting Costs of an Emerging Epidemic*. Available at: https://www.researchgate.net/publication/347946517_Atrial_Fibrillation_in_the_United_Kingdom_Predicting_Costs_of_an_Emerging_Epidemic (Accessed: 25 June 2026)[cite: 1].
- Scott, I.A., Hilmer, S.N., Reeve, E., Potter, K., Le Couteur, D., Rigby, D., Gnjdic, D., Del Mar, C.B., Roughead, E.E., Page, A. and Jansen, J. (2015) 'Reducing inappropriate polypharmacy: the process of deprescribing', *JAMA Internal Medicine*, 175(5), pp. 827-834[cite: 1].
- Sudore, R.L. and Fried, T.R. (2010) 'Redefining the "planning" in advance care planning: preparing lay-persons to choose and help make medical decisions', *Annals of Medicine*, 153(4), pp. 256-261[cite: 1].
- The King's Fund (2013) *Delivering better services for people with long-term conditions: Building the house of care*. London: The King's Fund[cite: 1].
- Vakili, B., Kaplan, R.C. and Chang, O.Y. (2011) 'Ethnic differences in the prevalence and incidence of atrial fibrillation', *Journal of the National Medical Association*, 103(5), pp. 415-420[cite: 1].
- Wagner, E.H., Austin, B.T., Davis, C., Hindmarsh, M., Schaefer, J. and Bonomi, A. (2001) 'Improving outcomes in chronic illness', *Managed Care Quarterly*, 9(4), pp. 14-23[cite: 1].

- WebMD (2025) *What to Know About AFib and Your Mental Health*. Available at: <https://www.webmd.com/heart-disease/atrial-fibrillation/afib-mental-health> (Accessed: 25 June 2026)[cite: 1].
- Wijffels, M.C., Kirchhof, C.J., Dorland, R. and Allessie, M.A. (1995) 'Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats', *Circulation*, 92(7), pp. 1954-1968[cite: 1].